Last reviewed · How we verify
Boniva (IBANDRONIC ACID)
Ibandronic Acid (Boniva), marketed by Hoffmann La Roche, is a bisphosphonate primarily indicated for hypercalcemia, competing in a well-established class of drugs with key competitors such as etidronic acid, pamidronic acid, alendronic acid, tiludronic acid, and risedronic acid. Boniva's mechanism of action, which involves binding to hydroxyapatite in bone to inhibit osteoclast-mediated bone resorption, provides a strong therapeutic foundation and differentiates it within the bisphosphonate class. The primary risk to Boniva's market position is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | IBANDRONIC ACID |
|---|---|
| Sponsor | Hoffmann La Roche |
| Drug class | Bisphosphonate |
| Target | Farnesyl pyrophosphate synthase |
| Modality | Small molecule |
| Therapeutic area | Bone |
| Phase | FDA-approved |
| First approval | 2003 |
Approved indications
- Hypercalcemia
- Postmenopausal osteoporosis
Common side effects
- Arthralgia
- Back pain
- Dyspepsia
- Diarrhea
- Abdominal pain
- Myalgia
- Headache
- Pain in extremity
Serious adverse events
- Serious adverse events
- All-cause mortality
- Ocular inflammation (iritis, scleritis)
Key clinical trials
- The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation (PHASE4)
- Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (NA)
- Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases (PHASE2)
- Denosumab Safety Assessment in Multiple Observational Databases
- Coral Calcium's Effect on Bone Density in Postmenopausal Women With and Without Ibandronate (PHASE2)
- Antiresorptive Effects of a 6-m Treatment Course With Ibandronate Plus Supplementation of Vitamine D and Calcium in Central America
- Efficacy and Safety of Oral Ibandronate in Patients of Liver Cirrhosis With Hepatic Osteodystrophy. (NA)
- Post-fracture Medication and Mortality
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Boniva CI brief — competitive landscape report
- Boniva updates RSS · CI watch RSS
- Hoffmann La Roche portfolio CI